Home Other Building Blocks 1009298-09-2
1009298-09-2,MFCD16660191
Catalog No.:AA00035B
1009298-09-2 | AZD8055
Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
98%(HPLC)
in stock  
$84.00   $59.00
- +
10mg
98%(HPLC)
in stock  
$117.00   $82.00
- +
50mg
98%(HPLC)
in stock  
$231.00   $162.00
- +
100mg
98%(HPLC)
in stock  
$365.00   $255.00
- +
500mg
98%(HPLC)
in stock  
$1,412.00   $989.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Q & A
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00035B
Chemical Name:
AZD8055
CAS Number:
1009298-09-2
Molecular Formula:
C25H31N5O4
Molecular Weight:
465.5447
MDL Number:
MFCD16660191
IUPAC Name:
[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol
InChI:
InChI=1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17-/m0/s1
InChI Key:
KVLFRAWTRWDEDF-IRXDYDNUSA-N
SMILES:
OCc1cc(ccc1OC)c1ccc2c(n1)nc(nc2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C
UNII:
970JJ37FPW
Properties
Computed Properties
 
Complexity:
659  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
465.238g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
465.554g/mol
Monoisotopic Mass:
465.238g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
93.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.6  

Synonyms
 
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol 
AZD8055 
CHEMBL1801204 
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol 
(5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol 
(5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol 
[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl]methanol 
KVLFRAWTRWDEDF-IRXDYDNUSA-N 
[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol 
AK109550 
PubChem22586 
cc-79 
AZD8055 
QCR-7 
MLS006010169 
SCHEMBL298416 
GTPL7714 
CHEBI:91329 
CTK3J9362 
AOB3532 
EX-A044 
SYN1166 
BCP02171 
1009298-09-2 
EX-A1549 
ABP000902 
BDBM50348452 
LM1148 
MFCD16660191 
s1555 
ZINC52509466 
AKOS016009126 
AN-1309 
BCP9000367 
AZD-8055 
CS-0067 
DB12774 
RL00063 
SB16567 
SS-4787 
AC-28424 
BC660053 
Benzenemethanol, 5-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy- 
HY-10422 
SMR004701277 
AZD 8055 
AB0033717 
AJ-112083 
AX8226378 
TX-015738 
ST24034773 
SW218287-2 
X7420 
AZ-12600000 
W-5658 
J-502775 
(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol 
BRD-K69932463-001-02-3 
AZD 8055;1009298-09-2 
[5-[2,4-bis((3s)-3-methylmorpholin -4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol 
{5-[2,4-bis(3S)(3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl}methanol 
5-[2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy benzenemethanol 
5-[2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-benzenemethanol 
AZD8055, Free Base 
D0K1VK 
C25H31N5O4 
ACN-031563 
[5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol 
A8214 
AZD-8055, 98% - 10MG 10mg 
C546624 
1201799-05-4 
UNII-970JJ37FPW 
970JJ37FPW 
Literature

Title: Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Journal: Molecular oncology 20140501

Title: mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.

Journal: Virology 20140301

Title: PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20130801

Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Journal: Bioorganic & medicinal chemistry letters 20130301

Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

Journal: British journal of cancer 20120925

Title: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Journal: Leukemia 20120601

Title: Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.

Journal: The Biochemical journal 20120515

Title: TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.

Journal: Cell metabolism 20120502

Title: Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Journal: Cancer research 20120401

Title: Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines.

Journal: Experimental neurology 20120201

Title: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Journal: PloS one 20120101

Title: Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.

Journal: The Journal of biological chemistry 20111118

Title: Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Journal: Cancer research 20110801

Title: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Journal: Cancer discovery 20110617

Title: mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Journal: Cancer research 20110615

Title: Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Journal: Biochemical Society transactions 20110401

Title: Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.

Journal: British journal of cancer 20110329

Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Journal: Journal of medicinal chemistry 20110310

Title: Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Journal: Bioorganic & medicinal chemistry letters 20100801

Title: Mammalian autophagy: core molecular machinery and signaling regulation.

Journal: Current opinion in cell biology 20100401

Title: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Journal: Cancer research 20100101

Title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Journal: Nature 20090716

Title: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Journal: Current biology : CB 20040727

Title: Regulation of longevity and stress resistance by Sch9 in yeast.

Journal: Science (New York, N.Y.) 20010413

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Additional Info:
Q & A